Skip to main content

Atypical Parkinsonism clinical trials at UCSF

2 in progress, 0 open to eligible people

Showing trials for
  • AMX0035 and Progressive Supranuclear Palsy

    Sorry, in progress, not accepting new patients

    A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.

    San Francisco, California and other locations

  • Parkinson's and Zoledronic Acid

    Sorry, in progress, not accepting new patients

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    San Francisco, California and other locations

Last updated: